ARK Investment Management LLC Increases Stock Position in Repare Therapeutics Inc. (NASDAQ:RPTX)

ARK Investment Management LLC increased its position in shares of Repare Therapeutics Inc. (NASDAQ:RPTX) by 7.7% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,821,560 shares of the company’s stock after buying an additional 200,677 shares during the period. ARK Investment Management LLC owned 0.07% of Repare Therapeutics worth $20,597,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Harbor Capital Advisors Inc. boosted its holdings in Repare Therapeutics by 14.2% during the fourth quarter. Harbor Capital Advisors Inc. now owns 48,055 shares of the company’s stock worth $351,000 after buying an additional 5,970 shares in the last quarter. Exchange Traded Concepts LLC grew its position in shares of Repare Therapeutics by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 13,585 shares of the company’s stock valued at $99,000 after purchasing an additional 3,445 shares during the period. American Century Companies Inc. grew its position in shares of Repare Therapeutics by 40.6% in the third quarter. American Century Companies Inc. now owns 17,904 shares of the company’s stock valued at $216,000 after purchasing an additional 5,174 shares during the period. GSA Capital Partners LLP acquired a new stake in shares of Repare Therapeutics in the third quarter valued at about $280,000. Finally, Lazard Asset Management LLC grew its position in shares of Repare Therapeutics by 260.2% in the third quarter. Lazard Asset Management LLC now owns 9,878 shares of the company’s stock valued at $119,000 after purchasing an additional 7,136 shares during the period. 85.09% of the stock is owned by hedge funds and other institutional investors.

Repare Therapeutics Trading Up 3.1 %

Shares of NASDAQ RPTX opened at $4.67 on Thursday. The company’s 50-day simple moving average is $6.33 and its 200-day simple moving average is $6.60. Repare Therapeutics Inc. has a 52-week low of $3.08 and a 52-week high of $13.85.

Repare Therapeutics (NASDAQ:RPTX) last posted its quarterly earnings results on Wednesday, February 28th. The company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.56) by ($0.11). The business had revenue of $13.05 million during the quarter, compared to analysts’ expectations of $15.92 million. Repare Therapeutics had a negative return on equity of 39.82% and a negative net margin of 183.43%. Equities analysts expect that Repare Therapeutics Inc. will post -2.74 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on RPTX. Bloom Burton lowered shares of Repare Therapeutics from a “buy” rating to an “accumulate” rating in a research report on Tuesday, February 13th. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Repare Therapeutics in a research report on Wednesday, February 21st.

Repare Therapeutics Profile

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.